KMT2A and acute myeloid leukemia: Also in the nested cohort of de novo pediatric AML MLL-rearranged cases (4 AF6, 7 AF9, 9 AF10, 1 FNBP1, 1 SEPT6, and 1 NRIP3)(S2 Table), of which 14/23 (60.9%) relapsed, no difference in miRNA expression profile was found between cases that relapsed and cases that recurred (p=0.429).